Aclaris Therapeutics, Inc. (ACRS) Form 8-K — Oct 27, 2026
Aclaris Therapeutics announced positive primary analysis results from Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma. In severe AD patients (78% vIGA 4 baseline), ATI-052 delivered a 45% placebo-adjusted EASI improvement and 78% placebo-adjusted EASI-50 at day 57, with itch improving 43% placebo-adjusted. In asthma, a single 480 mg dose produced a 59% mean FeNO reduction at day 15 versus 15% for placebo, plus a 200 mL placebo-adjusted FEV1 improvement (350 mL in the FEV1 <80% subgroup). Safety was favorable across both trials, with predominantly Grade 1 adverse events and no conjunctivitis observed.
Key figures
- Cash Position
- 204600000
- Ad trial patients
- 14
- Asthma trial patients
- 16
- Phase2b eoe trial start
- early 2027
- Skin proteome improvement
- 95%
- Ad easi50 placebo adjusted
- 78%
- Asthma feno reduction day15
- 59% (45 ppb) vs 15% placebo
- Asthma fev1 subgroup improvement
- 350 mL (FEV1 <80% predicted subgroup)
- Ad easi absolute improvement active arm
- 58%
- Ad easi placebo adjusted improvement day57
- 45%
- Ad ppnrs placebo adjusted improvement day57
- 43%
- Asthma fev1 placebo adjusted improvement day15
- 200 mL
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.